Clinical relevance of immunoactive mistletoe lectin-I

Recent investigations have shown that defined, non-toxic doses of the galactoside-specific mistletoe lectin (mistletoe lectin-I, a constituent of clinically approved plant extracts) have immunomodulatory potencies. The obvious ability of certain lectins (e.g. mistletoe lectin-I) to activate (non)-sp...

Full description

Saved in:
Bibliographic Details
Published inAnti-cancer drugs Vol. 8 Suppl 1; p. S53
Main Author Beuth, J
Format Journal Article
LanguageEnglish
Published England 01.04.1997
Subjects
Adjuvants, Immunologic - therapeutic use
Animals
Antineoplastic Agents, Phytogenic - pharmacology
Clinical Trials as Topic
Glioma - drug therapy
Glioma - immunology
Humans
Lectins - pharmacology
Mistletoe
Plant Lectins
Plant Preparations
Plant Proteins
Plants, Medicinal
Prospective Studies
Ribosome Inactivating Proteins, Type 2
Toxins, Biological - pharmacology
Online AccessGet more information

Cover

More Information
Summary:Recent investigations have shown that defined, non-toxic doses of the galactoside-specific mistletoe lectin (mistletoe lectin-I, a constituent of clinically approved plant extracts) have immunomodulatory potencies. The obvious ability of certain lectins (e.g. mistletoe lectin-I) to activate (non)-specific defence mechanisms supports the assumption that lectin-carbohydrate interactions may induce clinically beneficial immunomodulation. Initial clinical trials were promising and currently prospectively randomized multicentre trials are being performed to evaluate the ability of complementary mistletoe lectin-I treatment to reduce the rate of tumor recurrences and metastases, to improve the overall survival as well as the quality of life and to exert immunoprotection in cancer patients under tumor destructive therapy.
ISSN:0959-4973
1473-5741
DOI:10.1097/00001813-199704001-00012